查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1629876

全球线上血液监测设备市场 - 2025-2033

Global In-Line Blood Monitoring Devices Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 179 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年，全球线上血液监测设备市场达到100,630.41万美元，预计2033年将达到317,891.08万美元，2025-2033年预测期间复合年增长率为11.6%。

线上血液监测设备是用于连续测量和即时评估患者血液的各种关键参数的医疗仪器，通常在外科手术、重症监护或体外治疗（如心肺旁路、透析或 ECMO）期间使用。这些设备直接整合到血液循环路径中，无需重复采血即可进行非侵入性或微创监测。

对线上血液监测设备的需求正在经历显着增长，这归因于诸如需要体外循环的外科手术的增加以及移植等关键心血管手术的增加等因素。例如，根据麻省总医院布里格姆组织的数据，美国每年进行超过 90 万例心臟手术，包括冠状动脉绕道手术，世界各地进行的手术数量甚至更多。心臟手术是针对心臟及其大血管（包括肺动脉和主动脉）进行的。

此外，据 ScienceDirect 称，手术最近被认为是国家卫生系统不可或缺的一部分，但仍有约 50 亿人在需要时无法及时获得安全且负担得起的手术护理。每年有超过1700 万人死于手术可预防的疾病，而每年进行的3.13 亿例手术干预中，只有6% 发生在世界上最贫困的三分之一人口中，而这些人对手术护理的需求最高。这些不断增加的外科手术增加了对线上血液监测设备市场的需求。

市场动态：

驱动程式和限制

心血管疾病和危重疾病的盛行率不断增加

心血管疾病和败血症、中风和呼吸衰竭等危重疾病的盛行率不断上升，大大推动了线上血液监测设备市场的成长。这些情况需要持续即时监测关键血液参数，例如氧气水平、血气、电解质和血红蛋白。线上血液监测设备对于提供连续、非侵入性和准确的评估以优化重症监护病房 (ICU)、手术室和急诊护理机构的患者护理至关重要。

例如，根据世界卫生组织 (WHO) 的统计，心血管疾病 (CVD) 是全球主要死亡原因，估计每年夺走 1,790 万人的生命。心血管死亡人数的上升刺激了在冠状动脉绕道、心臟移植和其他心血管手术等高风险手术中对高阶监测的需求。

线上血液监测设备，特别是在心臟手术中，可以即时追踪血氧饱和度、pH 水平和二氧化碳浓度等参数，这对于在这些复杂手术过程中管理患者的稳定性至关重要。

全球高血压和其他心血管疾病危险因子的增加与持续监测血液参数以预防治疗期间或术后恢復期间併发症的需求日益增加直接相关。

例如，根据世界卫生组织的数据，全球估计有 12.8 亿 30-79 岁的成年人患有高血压，其中大多数（三分之二）生活在低收入和中等收入国家。据估计，46% 的成年人高血压患者并不知道自己患有这种疾病。不到一半（42%）的成年人高血压得到诊断和治疗。大约五分之一的成年人（21%）患有高血压，其病情得到控制。

与现有系统整合的复杂性

与现有医疗保健系统整合的复杂性是阻碍全球线上血液监测设备市场成长的关键挑战。虽然这些设备提供了连续即时监测的先进功能，但将它们与医院资讯系统 (HIS)、电子健康记录 (EHR) 和其他临床基础设施整合仍然是一个重大障碍。

许多医疗机构仍然依赖旧系统，这些系统无法与现代监控设备无缝连接。较旧的 EHR 系统或医院管理软体通常缺乏与较新的线上监控技术的兼容性。

医疗保健 IT 新闻的一项研究强调，80% 的医疗保健提供者仍然面临将更新的诊断技术整合到现有基础设施中的问题。线上血液监测设备需要与现有平台整合以进行资料传输和分析，但这些过时的系统可能会导致延迟、错误甚至资料遗失。

将连续性血液监测设备与医院 IT 系统整合会带来严重的资料安全和隐私问题。例如，根据 HIPAA 杂誌报导，2023 年 8 月，发现有 2,300 万笔医疗记录被洩露。在过去 12 个月中，平均每月有 9,989,003 笔医疗记录被洩露。

目录

第一章：市场介绍和范围

  • 报告的目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按模态分類的片段
  • 按产品分类的片段
  • 按应用程式片段
  • 按地区分類的片段

第 3 章：动力学

  • 影响因素
    • 司机
      • 心血管疾病和危重疾病的盛行率不断增加
      • 越来越多的外科手术需要体外循环
    • 限制
      • 与现有系统整合的复杂性
    • 机会
    • 影响分析

第 4 章：策略洞察与产业展望

  • 市场领导者和先驱
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的知名领导者
    • 拥有成熟产品的市场领导者
  • 新兴新创企业和关键创新者
  • CXO 观点
  • 最新进展和突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态

第 5 章：按模式分類的线上血液监测设备市场

  • 桌上型
  • 便携的

第 6 章： 线上血液监测设备市场（按产品）

  • 线上血液监测设备
  • 耗材

第 7 章：线上血液监测设备市场（按应用）

  • 心肺绕道手术
  • 移植程式
  • 先天性心臟病手术
  • ECMO
  • 其他的

第 8 章：线上血液监测设备市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 9 章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的主要发展
  • 公司基准化分析

第 10 章：公司简介

  • Terumo Corporation
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
    • SWOT分析
  • LivaNova PLC
  • Eurosets Srl
  • Spectrum Medical Ltd.

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: MD8906

The global In-line blood monitoring devices market reached US$ 100,630.41 thousand in 2024 and is expected to reach US$ 317,891.08 thousand by 2033, growing at a CAGR of 11.6% during the forecast period 2025-2033.

In-line blood monitoring devices are medical instruments used to continuously measure and assess various critical parameters of a patient's blood in real-time, typically during surgical procedures, intensive care or extracorporeal treatments such as cardiopulmonary bypass, dialysis, or ECMO (Extracorporeal Membrane Oxygenation). These devices are integrated directly into the blood circulation pathway, allowing for non-invasive or minimally invasive monitoring without requiring repeated blood sampling.

The demand for In-line blood monitoring devices is experiencing significant growth, which is attributed to factors such as growing surgical procedures requiring extracorporeal circulation and the growing critical cardiovascular procedures such as transplantations. For instance, according to the Mass General Brigham Organization, more than 900,000 cardiac surgeries, including coronary bypass surgeries, are performed in the U.S. every year, with even more taking place throughout the world. Cardiac surgery is performed on the heart and its large blood vessels, including the pulmonary arteries and the aorta.

Additionally, according to ScienceDirect, surgery has recently been recognized as an integral part of national health systems, yet approximately 5 billion people remain without timely access to safe and affordable surgical care when needed. More than 17 million people die of surgically preventable conditions every year, and only 6% of the 313 million surgical interventions taking place every year occur in the poorest one-third of the world's population, in whom the need for surgical care is highest. These rising surgical procedures increase the demand for in-line blood monitoring devices market.

Market Dynamics: Drivers & Restraints

Increasing prevalence of cardiovascular and critical conditions

The increasing prevalence of cardiovascular diseases and critical conditions like sepsis, stroke and respiratory failure is significantly driving the growth of the In-line blood monitoring devices market. These conditions require constant, real-time monitoring of critical blood parameters, such as oxygen levels, blood gases, electrolytes and hemoglobin. In-line blood monitoring devices are critical in providing continuous, non-invasive and accurate assessments to optimize patient care in intensive care units (ICUs), operating rooms and emergency care settings.

For instance, according to the World Health Organization (WHO), Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. This rising cardiovascular deaths has spurred the demand for advanced monitoring during high-risk procedures like coronary artery bypass, heart transplants and other cardiovascular surgeries.

In-line blood monitoring devices, particularly in cardiac surgeries, enable real-time tracking of parameters such as blood oxygen saturation, pH levels and carbon dioxide concentrations, essential for managing patient stability during these complex procedures.

The global rise in hypertension and other risk factors for cardiovascular diseases directly correlates to an increasing need for continuous monitoring of blood parameters to prevent complications during treatments or post-surgical recovery.

For instance, according to the World Health Organization, an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension, most (two-thirds) living in low- and middle-income countries. An estimated 46% of adults with hypertension are unaware that they have the condition. Less than half of adults (42%) with hypertension are diagnosed and treated. Approximately 1 in 5 adults (21%) with hypertension have it under control.

Complexity of integration with existing systems

The complexity of integration with existing healthcare systems is a key challenge hampering the growth of the global In-line blood monitoring devices market. While these devices offer advanced capabilities for continuous, real-time monitoring, integrating them with hospital information systems (HIS), electronic health records (EHR) and other clinical infrastructure remains a significant hurdle.

Many healthcare facilities still rely on legacy systems that were not designed to interface seamlessly with modern monitoring devices. Older EHR systems or hospital management software often lack compatibility with newer in-line monitoring technologies.

A study by Healthcare IT News highlighted that 80% of healthcare providers still face issues integrating newer diagnostic technologies into their existing infrastructure. In-line blood monitoring devices need to be integrated with existing platforms for data transmission and analysis, but these outdated systems can cause delays, errors or even data loss.

Integrating continuous blood monitoring devices with hospital IT systems raises significant data security and privacy issues. For instance, according to the HIPAA Journal, in August 2023, 23 million breached healthcare records were noticed. Over the past 12 months, an average of 9,989,003 healthcare records were breached each month.

Segment Analysis

The global In-line blood monitoring devices market is segmented based on modality, product, application and region.

Product:

The In-line blood monitoring devices segment is expected to dominate the market

The In-line blood monitoring devices segment is expected to dominate the global market. The In-line blood monitoring devices are crucial for diagnosing various medical conditions, including respiratory failure, metabolic disorders and conditions affecting oxygenation. Healthcare providers often utilize this during surgeries by integrating with heart-lung machines to make timely decisions regarding patient care. By assessing parameters such as partial pressures of oxygen (PaO2), carbon dioxide (PaCO2) and bicarbonate levels, clinicians can determine the adequacy of ventilation and oxygenation, guiding interventions like oxygen therapy or mechanical ventilation.

The companies are developing advanced in-line blood monitoring devices that meet the safety and regulatory standards that are set by the regulatory bodies. For instance, in March 2024, Terumo Cardiovascular received the FDA 510(k) clearance for its next-generation CDI OneView monitoring system. Terumo's CDI systems display patient parameters during cardiopulmonary bypass surgery to support perfusion safety and improve patient outcomes. This new CDI OneView system measures or displays up to 22 vital patient parameters, including oxygen delivery, cardiac index, area under the indexed oxygen delivery curve, oxygen extraction ratio and measured flow.

Additionally in August 2024, LivaNova received the FDA 510(k) clearance and CE mark for its Essenz in-line blood monitor. Essenz ILBM provides accurate and continuous measurement of essential blood parameters throughout cardiopulmonary bypass (CPB) procedures, according to LivaNova. It integrates into the next-generation Essenz perfusion system. Essenz enables perfusionists to access and manage reliable blood parameters directly from the system's cockpit. It eliminates the need for additional monitors or holders.

Geographical Analysis

North America is expected to hold a significant position in the In-line blood monitoring devices market share

North America is expected to hold the largest market share in the global In-line blood monitoring devices market. The increasing prevalence of chronic diseases and the rising number of cardiac surgeries driving the in-line blood monitoring devices market. The use of in-line monitoring devices in operating rooms for cardiac bypass surgeries is a crucial factor in the healthcare landscape of North America. With a substantial number of Coronary Artery Bypass Grafting (CABG) procedures performed annually, the demand for advanced monitoring technologies is essential for ensuring patient safety and enhancing surgical outcomes.

For instance, as per ScienceDirect research in June 2024, the average total cardiac surgical volume across 24 countries with available data was 123.2 surgeries per 100,000 population per year. This figure varies significantly by country, with South Korea reporting a low of 27.3 surgeries per 100,000 and the United States exhibiting the highest rate at 271.5 surgeries per 100,000. This increasing surgery number demands in-line blood monitoring devices in the U.S. market.

The increasing prevalence of cardiovascular diseases is driving the need for advanced monitoring devices during surgical interventions. As a greater number of patients undergo surgeries that involve cardiopulmonary bypass, there is a demand for dependable in-line blood monitoring devices.

For instance, according to the Centers for Disease Control and Prevention (CDC), cardiovascular disease remains the leading cause of death for both men and women across various racial and ethnic groups in the United States. In 2022, around 702,880 individuals lost their lives to heart disease, which translates to approximately 1 in every 5 deaths. With a person succumbing to cardiovascular disease every 33 seconds, there is an urgent need for prompt and precise medical interventions in clinical environments. The implementation of continuous blood monitoring can significantly enhance patient outcomes during critical surgical procedures.

Asia-Pacific is growing at the fastest pace in the In-line blood monitoring devices market

The Asia-Pacific region is experiencing the fastest growth in the In-line blood monitoring devices market. The increasing number of bypass surgeries and heart-lung transplants in the Asia-Pacific region is a significant driving factor for the in-line monitoring devices market indicating an increasing demand for surgical interventions aimed at treating severe cardiovascular diseases. As more patients undergo these procedures, there is a corresponding need for effective in-line monitoring devices that can continuously track vital signs, including heart rate, blood pressure, oxygen saturation, and other critical parameters during surgery.

The increase in Coronary Artery Bypass Grafting (CABG) procedures in India signifies a growing demand for effective cardiac interventions. As more patients undergo CABG, the need for reliable in-line blood monitoring devices becomes crucial to ensure patient safety and optimize surgical outcomes. Continuous monitoring of vital parameters such as blood pressure, heart rate, and oxygen saturation is essential during these complex surgeries.

For instance, according to the Times of India (TOI), the increase in bypass surgeries among patients in their early to mid-30s by 30% over the past decade, with an annual rise of 5%, is a significant driving factor for the in-line blood monitoring devices market. This trend reflects a concerning shift in cardiovascular health, indicating that heart attacks and related diseases are becoming more prevalent in younger individuals.

Additionally, according to the Journal of the Practice of Cardiovascular Sciences, in India, 1,328 heart transplants, 475 lung transplants, 128 Left Ventricular Assist Device (LVAD) implants, and 61 lung transplants for COVID-19 lung disease completed by March 2023, highlights significant advancements in the field of organ transplantation. The annual figures show a steady number of procedures, with 129 lung transplants performed in 2023 and 62 in 2024 up to July, alongside 102 heart transplants in 2023 and 62 in 2024 until July. This upward trend in complex surgical procedures is a crucial driver for the inline monitoring devices market in the region.

Competitive Landscape

The major global players in the In-line blood monitoring devices market include Terumo Corporation, LivaNova PLC, Eurosets S.r.l. and Spectrum Medical Ltd.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global In-line blood monitoring devices market report delivers a detailed analysis with 44 key tables, more than 48 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Modality
  • 2.4. Snippet by Product
  • 2.5. Snippet by Application
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Increasing Prevalence of Cardiovascular and Critical Conditions
      • 3.1.1.2. Growing Surgical Procedures Requiring Extracorporeal Circulation
    • 3.1.2. Restraints
      • 3.1.2.1. Complexity of Integration with Existing Systems
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. In-Line Blood Monitoring Devices Market, By Modality

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 5.1.2. Market Attractiveness Index, By Modality
  • 5.2. Bench Top*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Portable

6. In-Line Blood Monitoring Devices Market, By Product

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 6.1.2. Market Attractiveness Index, By Product
  • 6.2. In-Line Blood Monitoring Devices*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Consumables

7. In-Line Blood Monitoring Devices Market, By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Cardiopulmonary Bypass Procedures*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Transplant Procedures
  • 7.4. Congenital Heart Procedures
  • 7.5. ECMO
  • 7.6. Others

8. In-Line Blood Monitoring Devices Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Terumo Corporation*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. LivaNova PLC
  • 10.3. Eurosets S.r.l.
  • 10.4. Spectrum Medical Ltd.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us